Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study

BACKGROUND: Heart failure (HF) is a global leading cause of mortality despite implementation of guideline directed therapy which warrants a need for novel treatment strategies. Proof-of-concept clinical trials of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, have shown prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Tassell, Benjamin, Mihalick, Virginia, Thomas, Georgia, Marawan, Amr, Talasaz, Azita H., Lu, Juan, Kang, Le, Ladd, Amy, Damonte, Juan Ignacio, Dixon, Dave L., Markley, Roshanak, Turlington, Jeremy, Federmann, Emily, Del Buono, Marco Giuseppe, Biondi-Zoccai, Giuseppe, Canada, Justin M., Arena, Ross, Abbate, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198622/
https://www.ncbi.nlm.nih.gov/pubmed/35706006
http://dx.doi.org/10.1186/s12967-022-03466-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198622/
https://www.ncbi.nlm.nih.gov/pubmed/35706006
http://dx.doi.org/10.1186/s12967-022-03466-9

Ejemplares similares